PROCESS OF DELIVERING A POLYNUCLEOTIDE TO A MUSCLE CELL VIA THE VASCULAR SYSTEM

• US 20020001574A1
• Filed: 12/30/1997
• Published: 01/03/2002
• Est. Priority Date: 12/13/1995
• Status: Abandoned Application

• Current Assignee: Jon A. Woiff, Stuart J. Knechtle, Vladimir Budker
• Original Assignee: Jon A. Woiff, Stuart J. Knechtle, Vladimir Budker
• Inventors: BUDKER, VLADIMIR, KNECHTLE, STUART J., WOIFF, JON A.
• Application Number:
  US09/000,533
• Publication Number:
  US 20020001574A1
• Time in Patent Office: Days
• US Class Current: 424/93.1
• CPC Class Codes: A61K 48/0008 characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
• CPC Class Codes: A61K 48/0075 characterised by an aspect of the delivery route, e.g. oral, subcutaneous

Abstract

A process for delivering a polynucleotide into a parenchymal cell in a mammal, comprising, transporting the polynucleotide into a blood vessel communicating with the parenchymal cell in tissue or organ of the mammal such that the polynucleotide is transfected into the parenchymal cell. More specifically, the parenchymal cell consists of a muscle cell and the polynucleotide consists of a viral vector.

Claims

1. A process for delivering a polynucleotide to a muscle cell, comprising:

inserting the polynucleotide into a vessel for delivery to the muscle cell such that the polynucleotide is transfected into the muscle cell.

2. The process of claim 1 wherein the polynucleotide is selected from the group consisting of RNA and DNA.

3. The process of claim 2 wherein the polynucleotide is a viral vector.

4. The process of claim 3 wherein the polynucleotide is a vector selected from the group consisting of adenoviral and retroviral.

5. The process of claim 4 wherein the retroviral vector is selected from the group consisting of VSV G, lentivirus.

6. The process of claim 1 wherein the vessel consists of a blood vessel having a permeable wall.

7. The process of claim 6 wherein the blood vessel is selected from the group consisting of afferent and efferent vessels.

8. The process of claim 7 wherein the permeability is increased by a method selected from the group consisting of:

increasing hydrostatic pressure on the blood vessel wall, increasing osmotic pressure on the blood vessel wall, and introducing a biologically-active molecule to the blood vessel wall.

9. The process of claim 8 wherein the hydrostatic pressure is increased by obstructing outflow from the blood vessel.

10. A process for delivering a polynucleotide to a muscle cell for expressing a protein, comprising:

a) inserting the polynucleotide into a vessel having a permeable wall; and

,

b) increasing the permeability of the wall for a time sufficient to allow delivery of the polynucleotide.

11. The process of claim 10 wherein the polynucleotide is selected from the group consisting of RNA and DNA.

12. The process of claim 11 wherein the polynucleotide consists of a viral vector.

13. The process of claim 12 wherein the polynucleotide is a vector selected from the group consisting of adenoviral and retroviral.

14. The process of claim 13 wherein the retroviral vector is selected from the group consisting of VSV G, lentivirus.

15. The process of claim 11 wherein the vessel consists of a blood vessel having a permeable wall.

16. The process of claim 15 wherein the blood vessel is selected from the group consisting of afferent and efferent vessels.

17. The process of claim 16 wherein the permeability is increased by a method selected from the group consisting of:

increasing hydrostatic pressure on the blood vessel wall, increasing osmotic pressure on the blood vessel wall, and introducing a biologically-active molecule to the blood vessel wall.

18. The process of claim 17 wherein the hydrostatic pressure is increased by obstructing outflow from the blood vessel.